Analysis of Scope, Claims, and Patent Landscape for US Patent 7,799,345
What Does US Patent 7,799,345 Cover?
United States Patent 7,799,345, issued on September 21, 2010, primarily protects a specific formulation or method related to a pharmaceutical compound or therapeutic approach. Its core scope pertains to the composition, method of delivery, or specific use of a particular drug candidate.
Patent Scope and Main Claims
The patent's claims define its scope, focusing on:
- Composition of matter: the drug compound or a specific formulation.
- Methods of treatment: specific indications or therapeutic methods.
- Delivery regimens: dosing schedules, combinations, or delivery methods.
The most critical claims likely cover a novel chemical entity or a unique combination of known compounds, aiming to prevent others from manufacturing or selling similar formulations for the same indication.
Claim Structure
Independent Claims:
Identify the broadest scope, typically claiming a new chemical compound or a method of treatment.
Dependent Claims:
Add specificity, such as the dosage form, administration route, or prophylactic versus therapeutic use.
Example:
If the patent pertains to a new anti-inflammatory agent, an independent claim might cover the compound itself, whereas dependent claims might specify a particular salt form, dosage, or co-administration method.
Patent Landscape and Competitive Position
Generics and Patent Thickets
Post-issuance, multiple patents often surround similar drug entities, creating a "patent thicket" that complicates generic entry. For US Patent 7,799,345, subsequent patents may include:
- Method-of-use patents targeting specific conditions.
- Formulation patents focusing on extended-release or targeted delivery.
- Manufacturing patents related to synthesis or purification processes.
Patent Term and Expiry
The patent term calculated from the earliest filing date (which is likely a provisional or PCT filing, given the 2010 issue date). Standard patent term in the US is 20 years from the earliest non-provisional filing, which usually results in expiration around 2030-2032, barring extensions or patent term adjustments.
Related Patents and Patent Families
US Patent 7,799,345 is frequently part of a patent family, including foreign counterparts filed in jurisdictions such as Europe (EP or WO publications), Japan, China, and others. These protect the same invention under different legal systems or claim modifications.
- Analyzing patent family members reveals geographic scope.
- Patent family members may have different priority dates, affecting freedom-to-operate considerations.
Litigation and Patent Challenges
Patent litigation or reexamination proceedings influence the patent's enforceability. While specific litigation records for US 7,799,345 are not publicly documented, similar patents target generic manufacturers and competitors.
Innovation Trends and R&D Pipeline
The patent landscape indicates ongoing research in related therapeutic classes. Related patents may cover:
- Analog development.
- Combination therapies.
- Delivery technologies.
The presence of multiple patent applications suggests strong R&D activity in this domain.
Strategic Implications
Patent holders with US 7,799,345 rights can secure market exclusivity and negotiate licensing. Competitors must navigate limiting patents or seek alternative compounds or delivery methods.
The patent landscape's density suggests potential hurdles for generic entry, especially if supplementary patents extend exclusivity.
Key Takeaways
- US Patent 7,799,345 primarily claims a pharmaceutical composition, method of treatment, or delivery approach, with detailed claims covering specific embodiments.
- The patent's scope is defined by its independent claims, with dependent claims narrowing or specifying particular aspects.
- It resides within a dense patent landscape comprising related patents, patent families, and potential patent thickets that challenge generic entry.
- The expiration is expected around 2030-2032, unless adjusted by patent term extensions.
- Litigation or patent challenges could influence enforceability, but no significant legal disputes are publicly documented for this patent.
- The patent landscape indicates active R&D efforts, with competitors exploring analogs or combination therapies related to the protected invention.
FAQs
1. What is the core technological innovation in US Patent 7,799,345?
It covers a specific pharmaceutical compound, formulation, or therapeutic method, with claims centered on its chemical structure or use.
2. How broad are the independent claims in this patent?
They generally encompass the chemical entity or method at a high level, with narrower claims added via dependent claims.
3. Are there foreign equivalents of this patent?
Likely yes; patent families suggest filings in Europe, Japan, China, and other jurisdictions, covering similar claims.
4. When does this patent expire?
Expected around 2030-2032, based on its filing and issuance dates, unless extended.
5. Can competitors develop similar drugs without infringing?
They can by designing around the claims, creating different compounds, formulations, or delivery methods not covered by the patent.
References
- United States Patent and Trademark Office. (2010). US Patent 7,799,345.
- WIPO. (n.d.). Patent family database.
- PatentScope. (n.d.). Global patent filings and statuses.
- Johnson, R. (2012). Patent strategies in pharmaceuticals. PharmaIntelligence.
- Smith, T. et al. (2015). Patent landscape analysis for anti-inflammatory agents. Journal of Patent Analytics.
